# A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

> **NCT01248949** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 162 (actual)

## Conditions studied

- Advanced Solid Tumors
- Advanced Recurrent Ovarian Tumors

## Interventions

- **DRUG:** MEDI3617
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01248949
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-07
- **Final completion:** 2015-10
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248949, "A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01248949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*